@phdthesis{Reggane2019, author = {Reggane, Maude}, title = {Lowering lattice forces of crystalline bases}, doi = {10.25972/OPUS-16380}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-163803}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2019}, abstract = {The number of active pharmaceutical ingredients (APIs) exhibiting a low solubility in aqueous media or a slow dissolution rate kept rising over the past years urging formulation scientists to explore new ways to tackle poor solubility and to enable oral absorption from such compounds. Bioavailability of poorly water-soluble compounds can be improved by increasing the dissolution rate and/or by increasing the gastro intestinal concentration through transient supersaturation. The dissolution rate of the API can be typically modified by the choice of the physical form, the polymorphic form, the powder surface area, and the local pH, while a transient supersaturation can be extended mainly by nucleation or crystallization inhibiting effects. In the present thesis, three strategies were explored to tailor the dissolution rate, the supersaturation and the hydrotropic solubilization of APIs, weak bases, respectively. The first part of this thesis followed a bioinspired approach to extend the kinetic solubility of salts and co-crystals. API salts and co-crystals are high energy forms that can generate supersaturated solutions with respect to any more stable form, typically the most stable API form in physiological environment. The transient kinetic stabilization of supersaturated states, also termed "parachute effect", is considered to improve bioavailability and is one aspect of the formulation that can be tailored. Inspiration from plants, which store high concentrations of aromatic bases in their vacuoles via complexation with polyphenols, sparked the evaluation to use hydroxybenzoic acid derivatives for salt or co-crystal engineering. Imatinib was chosen as the model compound for this investigation as its aromaticity and flat molecular architecture could favor interactions with hydroxybenzoic acid derivatives. One 1:1 Imatinib syringate co-crystal (I-SYA (1:1)) and one 1:2 Imatinib syringate co-crystal salt (I-SYA (1:2)) were obtained. Their dissolution assays in simulated intestinal fluid (SIF; a 50 mM phosphate buffer of pH 6.8) revealed that they formed stable solutions for several hours and days, respectively, in contrast to the marketed Imatinib mesylate salt (approx. 1h). This kinetic stability in solution was linked to the nucleation inhibition of the less soluble Imatinib hydrate by syringic acid (SYA). In solution 1H-NMR studies evidenced the aggregation of Imatinib and SYA. The amphiphilic nature of both Imatinib and SYA is considered to drive their association in solution, additionally, multiple intermolecular interactions such as hydrogen bonds and π-π stacking are likely to contribute. The association in solution enabled a phase of extended supersaturation, i.e., a parachute against desupersaturation, while no negative impact of aggregation on the permeability of both Imatinib and SYA was observed. A prerequisite to reach supersaturation is a rapid dissolution and release of the API from the formulation. Accordingly, the second and third part of this thesis is focused on the so-called "spring effect" of amorphous solid dispersions (ASDs). The addition of a hydrotropic agent, meaning a molecule that can solubilize poorly water-soluble APIs in aqueous solutions (well-known examples of hydrotropes are benzoic acid and nicotinamide) into an amorphous Ciprofloxacin-polymer matrix led to ternary systems with a significantly faster release and higher concentration of the API in SIF as compared to binary ASDs consisting of Ciprofloxacin (CPX) and polymer only. The stronger spring could be rationalized by an improved wetting of the ASD, or/and by a hydrotropic solubilization effect, although these hypotheses need further investigation. Marked differences in the dissolution profiles of binary ASDs were observed in biorelevant fasted simulated intestinal fluid (FaSSIF; a medium containing Na taurocholate (3 mM) and lecithin (0.75 mM) at pH 6.5) as compared to SIF. In FaSSIF, API release from binary polymeric ASDs was largely improved, and the duration of supersaturation was extended. This suggests that the bile salt Na taurocholate and lecithin present in FaSSIF do improve both dissolution rate and supersaturation of ASDs, the two pillars of ASDs as oral enabling formulations. Indeed, bile salts are endogenous surfactants which, together with phospholipids, play an important role in the wetting, solubilization, and absorption of lipophilic compounds. The aim of the third part of the present thesis was to study ASDs as formulation principles reducing the strong positive food effect of Compound A. By inclusion of Na taurocholate (NaTC) within the matrix of polymeric ASDs a significant improvement of the dissolution rate and the kinetic solubility in SIF were achieved. Transient supersaturated states of up to four orders of magnitude over the equilibrium solubility were obtained. Two ASDs were selected for further in vivo evaluation in dog. The first was a NaTC/Eudragit E based ASD meant to dissolve and release Compound A in the acidic environment of the stomach, where its solubility is the highest. The second relied on the release of Compound A in the neutral environment of the duodenum and jejunum by using an enterically dissolving polymer, HPMC-P. Releasing the API at the site of its putative absorption was an attempt to control supersaturation levels in the duodenum and to prevent portioning and thus dilution effects during transfer from the stomach. In fasted dogs, exposure from the NaTC/HPMC-P ASD was close to that of the reference Compound A formulation under fed conditions, which suggests an improved dissolution rate and kinetic solubility under fasted conditions (historical data). The exposure from the NaTC/Eudragit E ASD was twice as low as from the NaTC/HPMC-P ASD, and also lower compared to Compound A reference formulation, whereas in vitro the parachute effect of the NaTC/Eudragit E ASD was largely superior to that of the NaTC/HPMC-P ASD. A difference in the extend of the parachute could be related to differences in the thermodynamic activity of dissolved molecules from the two ASDs. Indeed, the high instability of the NaTC/HPMC-P ASD could stem from a high thermodynamic activity driving diffusion through membranes, whereas less instable solutions of NaTC/Eudragit E could indicate solubilization effects which often translate into a lower flux through the biological membrane. Additionally, the pH of the environment where dissolution takes place might be an important factor for absorption, and could also account for the difference in exposure from the two ASDs. The aim of this thesis was to explore how the intimate environment of weak, poorly soluble bases could be functionalized to improve dissolution rate and kinetic solubility. The investigations highlighted that the performance of enabling oral delivery formulations of weak bases in aqueous media can be enhanced at different levels. At one end initial dissolution rate of ASDs can be tailored by introducing hydrotropes or/and bile salts within the polymeric matrix of ASDs. Bile salts, when combined with appropriate polymers, had also a precipitation inhibition effect enabling the maintenance of supersaturation for a bio-relevant period of time. These results set the ground for further investigations to comprehend specific interactions between bile salts and APIs, and potentially polymers at the molecular level. It will be interesting to explore how such complex systems can be exploited in the formulation design of poorly water-soluble APIs. In addition, it was observed that the duration of supersaturation generated by salts/co-crystals can be extended by the pertinent selection of counterions or coformers. The in vivo relevance of these tunings remains to be evaluated, as translation from closed, in vitro systems to the highly dynamic gastrointestinal environment is not straightforward. A better understanding of the contribution of each kinetic stage (dissolution, supersaturation, and precipitation) and their interplay with physiological factors impacting absorption is essential to facilitate the design of formulations with improved pharmacokinetics.}, subject = {Kokristallisation}, language = {en} } @phdthesis{Plank2019, author = {Plank, Christina}, title = {Untersuchung von Dihydroisochinolinonderivaten als m{\"o}gliche Inhibitoren von Hsc70}, doi = {10.25972/OPUS-16265}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-162655}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2019}, abstract = {Einhergehend mit einer steigenden Lebenserwartung nimmt auch die Zahl der am Multiplen Myelom Erkrankten zu. Bis dato gibt es nur wenige Therapieans{\"a}tze dieser selten vorkommenden Blutkrebserkrankung. Im Zusammenhang mit der Entstehung des Multiplen Myeloms stehen vor allem zwei bedeutende Hitzeschockproteine: Hsp90 und Hsp70. Beide haben die Aufgabe, Zellen vor Apoptose zu sch{\"u}tzen. In proliferierenden Plasmazellen ist eine {\"U}berexpression an Hsp90 zu beobachten. Entwickelte Inhibitoren f{\"u}hrten zwar zu einer verminderten Hsp90-Aktivit{\"a}t, allerdings wurde diese durch eine vermehrte Expression von Hsp70 kompensiert, weshalb Myelomzellen weiterhin proliferierten. Aus diesem Grund bietet sich Hsp70 als weiterer Angriffspunkt in der Therapierung des Multiplen Myeloms an. Die bislang entwickelten Inhibitoren binden entweder an die Nukleotid- oder Substratbindedom{\"a}ne. Da beide Stellen unspezifisch sind, wurden durch virtuelles Screening potenzielle Inhibitoren f{\"u}r Hsp70 identifiziert, welche in vitro und in vivo tats{\"a}chlich Effekte hinsichtlich der Herunterregulierung von Hsp70 zeigten. Ob die entwickelten Substanzen jedoch direkt an Hsp70 binden, war die Fragestellung der vorliegenden Arbeit. In dieser Arbeit wurde untersucht, inwiefern die entwickelten Inhibitoren an Hsp70 binden und dieses inhibieren. Die humane Hsp70-Familie besitzt sechzehn Mitglieder, die alle {\"a}hnliche Aufgaben und Strukturmerkmale aufweisen. F{\"u}r die durchgef{\"u}hrten Versuche wurde die Hsp70-Isoform Hsc70 verwendet. In einem Protein-Ligand-Assay konnte gezeigt werden, dass die meisten Verbindungen durch Aggregatbildung zu einer Inhibition von Hsc70 f{\"u}hrten. Durch Zugabe von Detergenz konnten die gebildeten Aggregate aufgebrochen und so der Inhibitionseffekt aufgehoben bzw. deutlich reduziert werden. Damit konnte gezeigt werden, dass die in Zell- und Mausversuchen beobachteten Effekte vermutlich nicht auf eine direkte Inhibition von Hsc70 zur{\"u}ckzuf{\"u}hren sind. Ob diese Effekte nun ebenfalls auf Aggregatbildung beruhen oder aber ein anderes Protein als das vermutete Hsc70 inhibiert wird, was {\"u}ber eine Signalkaskade zur Inhibition von Hsc70 f{\"u}hrt, w{\"a}re eine interessante Fragestellung f{\"u}r weitere Untersuchungen. Da sowohl in NMR-Versuchen als auch dem durchgef{\"u}hrten Protein-Ligand-Assay gezeigt werden konnte, dass die vormals als potenzielle Inhibitoren entwickelten Verbindungen nur schwach aktiv sind, wurde durch Fragment-basierte Ans{\"a}tze eine andere Bindestelle f{\"u}r m{\"o}gliche Inhibitoren identifiziert. Hierbei konnte N-Acetyl-D-Glucosamin in der Nukleotidbindedom{\"a}ne von Hsc70 detektiert werden. Hieraus k{\"o}nnten sich neue Ans{\"a}tze zur Entwicklung neuartiger in silico entwickelter Hsc70-Inhibitoren ergeben. Ausgangspunkt f{\"u}r die Docking-Studien zur Entwicklung neuer Hsp70-Inhibitoren war die Kristallstruktur von bHsc70 ED 1-554, einer trunkierten Doppelmutante des nativen Hsc70. Bis dato ist diese 554 Aminos{\"a}uren umfassende Mutante die einzige Hsc70-Variante von der die Zweidom{\"a}nenstruktur kristallisiert werden konnte. F{\"u}r dieses Konstrukt wurde zun{\"a}chst ein optimiertes Aufreinigungsprotokoll entwickelt, um dann Kristallisationsversuche mit ausgew{\"a}hlten AH-Verbindungen, die in den Docking-Studien entwickelt wurden, durchzuf{\"u}hren. Hierbei konnte jedoch keine Bindung festgestellt werden. Die Kristallisation mit Ver-155008, einem bekannten Hsc70-Inhibitor, f{\"u}hrte jedoch zur ersten Zweidom{\"a}nenstruktur von Hsc70 mit gebundenem Ver-155008. Neben der obigen Fragestellung wurde außerdem untersucht, wie funktional aktiv das trunkierte Hsc70-Konstrukts ist. Hier zeigte sich, dass aufgrund des fehlenden C-Terminus zwar eine geringe Aktivit{\"a}t von 30 \% im Vergleich zur Volll{\"a}nge zu beobachten war. F{\"u}r eine nahezu vollst{\"a}ndige R{\"u}ckfaltungsaktivit{\"a}t ist aber der C-Terminus essentiell. Weiterhin konnte in ITC-Versuchen der Kd-Wert von Ver-155008 an die verwendete Mutante ermittelt werden, der dem bereits bekannten Kd von Ver-155008 an das native Hsc70 {\"a}hnlich ist.}, subject = {Hitzeschockproteine}, language = {de} } @phdthesis{Goetz2019, author = {G{\"o}tz, Marcus Rudolf}, title = {Effiziente Synthese von Dronabinol und weiterer cannabinoider Derivate und deren pharmakologische Charakterisierung}, doi = {10.25972/OPUS-16662}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-166625}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2019}, abstract = {In dieser Arbeit wurde ein Verfahren zur effizienten Herstellung von (-)-trans-Cannabidiol (CBD, 10), (-)-trans-Δ9-Tetrahydrocannabinol (Dronabinol, 21) und (-)-trans-Cannabidivarin (CBDV, 30) durch kontinuierliche Synthese untersucht und entwickelt. CBD konnte durch kontinuierliche Synthese in drei Schritten aus Olivetolcarbons{\"a}uremethylester (OM, 6) und Menthadienol G (3) mit einer Ausbeute von 41 \% synthetisiert werden. Bei optimierten Bedingungen betrug die Reinheit nach Kristallisation > 99 \%. Die Stereochemie konnte durch R{\"o}ntgenstrukturanalyse eindeutig als 1R,6R bestimmt werden. Vorteilhaft war dabei, dass Toluol anstatt eines chlorierten L{\"o}sungsmittels verwendet werden konnte. Weitere Vorteile waren die kurze Reaktionszeit und die Tatsache, dass die Synthese bei Raumtemperatur durchgef{\"u}hrt werden konnte. Es konnten f{\"u}nf Nebenprodukte detektiert und identifiziert werden, wovon eines Dronabinol war. Bei optimierten Reaktionsparametern konnte eine Ausbeute an Dronabinol von 64,5 \% erreicht werden. Durch Simulated Moving Bed (SMB)-Chromatographie konnte Dronabinol kontinuierlich mit einem Gehalt von > 95 \% hergestellt werden. Nach der Synthese waren vier Verunreinigungen detektierbar, und zwar Olivetol (17), CBD, Exo-Tetrahydrocannabinol (Exo-THC, 23) und Δ8-Tetrahydrocannabinol (Δ8-THC, 22). Durch die SMB-Aufreinigung konnten alle Verunreinigungen auf einen monographiekonformen (USP 37) Gehalt abgereichert werden. Nach der finalen destillativen Aufarbeitung trat eine noch nicht identifizierte Verunreinigung in einem Gehalt von ca. 0,4 Fl{\"a}chen-\% auf. CBDV konnte durch kontinuierliche Synthese in drei Schritten aus Divarincarbons{\"a}uremethylester (DM, 25) und Menthadienol G synthetisiert werden. Die Ausbeute betrug ca. 30 \%, die Reinheit nach Kristallisation > 99 \%. Es konnten f{\"u}nf Nebenprodukte detektiert werden, die im Rahmen dieser Arbeit nicht weiter charakterisiert wurden. Der Syntheseweg bietet durch Modifikation der Seitengruppen an Position 6 (R1) und Position 5 (R2) der Alkylbenzol-Gruppe Zugang zu synthetischen Cannabinoiden mit einem CBD- oder CBDV-Grundger{\"u}st. Es wurden neun neue Cannabinoide hergestellt: 2-Hydroxyethylcannabidiolat (2-HEC, 31), 2-Hydroxypentylcannabidiolat (2 HPC, 32), Glycerylcannabidiolat (GCBD, 33), Cyclohexylcannabidiolat (CHC, 34), Hexylcannabidiolat (HC, 35), N-Methylsulfonylcannabidiolat (NMSC, 36), 2 Hydroxyethylcannabidivarinolat (2-HECBDV, 37), Cyclohexylcannabidivarinolat (CHCBDV, 38) und Hexylcannabidivarinolat (HCBDV, 39). Die Bindungsaffinit{\"a}t wurde in Cannabinoid-Rezeptor-transfizierten HEK293EBNA-Zellen untersucht, die intrinsische Aktivit{\"a}t in CHO-Zellen, die Induktion von NF-κB (nuclear factor kappa B) sowie von NFAT (nuclear factor of activated T cells) in Jurkat-T Zellen, die Induktion proinflammatorischer Zytokine und Chemokine (Interleukin(IL)-6, IL-1β, CC Chemokinligand 2' (CCL2) und Tumornekrosefaktor(TNF)-α) auf mRNA-Ebene in RAW264.7-Makrophagen und die Expression von proinflammatorischen Zytokinen (IL-1β, IL-6, IL-8, TNF-α) und Prostaglandin E2 (PGE2) auf Proteinebene in prim{\"a}ren humanen Monozyten. Die CBD-Derivate zeigten eine h{\"o}here Selektivit{\"a}t f{\"u}r CB2-Rezeptoren. Die CBDV-Derivate HCBDV und CHCBDV zeigten eine spezifische Bindung an CB1- und CB2-Rezeptoren im nanomolaren Bereich. 2-HEC, 2-HPC, GCBD und NMSC wirkten als Agonisten an CB2- und als Antagonisten am CB1-Rezeptor. CHC band an CB1 und CB2 im submikromolaren Bereich und schien ein Agonist f{\"u}r beide Rezeptoren zu sein. 2- HECBD wirkte als Agonist auf CB2-Rezeptoren und als Antagonist auf CB1-Rezeptoren. In Jurkat-T Zellen hemmte NMSC dosisabh{\"a}ngig die Aktivit{\"a}t von NF-κB sowie von NFAT. 2-HEC, 2-HPC und GCBD hemmten die Expression von NFAT ebenfalls dosisabh{\"a}ngig. CHC und HC reduzierten dosisabh{\"a}ngig die Expression von IL-1β- und CCL2-mRNA in RAW264.7-Makrophagen. NMSC hemmte in geringeren Dosen IL-1β, CCL2 sowie TNF-α und induzierte in h{\"o}heren Dosen einen starken Anstieg der IL-6-mRNA. In prim{\"a}ren humanen Monozyten hemmten 2 HEC und GCBD konzentrationsabh{\"a}ngig die Synthese von IL-1β, IL-6 und TNF-α. 2-HPC hemmte dosisabh{\"a}ngig die Bildung von TNF-α und IL-6. HC verminderte dosisabh{\"a}ngig die Freisetzung von TNF-α und IL-6. NMSC steigerte die durch LPS erh{\"o}hte Freisetzung von IL-1β noch weiter, hemmte aber TNF-α, IL-8 und PGE2. Die hier untersuchten CBD- und CBDV-Derivate sind geeignet, gezielt an Cannabinoid-Rezeptoren zu wirken. Einige der Derivate k{\"o}nnten als selektive CB2-Agonisten genutzt werden. Die L{\"a}nge des aliphatischen Rests an R2 von CBD (Pentyl-Cannabinoiden) und CBDV (Propyl-Cannabinoiden) korrelierte nicht mit der Bindungsaffinit{\"a}t. Eine h{\"o}here Polarit{\"a}t an R1 (2-HECBDV > NMSC > GCBD > 2-HEC) schien demgegen{\"u}ber die agonistische Aktivit{\"a}t an CB2 zu beg{\"u}nstigen. Um den Ergebnissen zur Beziehung zwischen Struktur und Wirkung noch mehr Bedeutung zu geben, w{\"a}ren weitere synthetische Derivate und deren Testung notwendig.}, subject = {Dronabinol}, language = {de} } @phdthesis{Wahl2019, author = {Wahl, Joachim}, title = {The Use of Ionic Liquids in Capillary Electrophoresis Enantioseparation}, doi = {10.25972/OPUS-17639}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-176397}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2019}, abstract = {Two chiral chemical molecules being mirror images of each other, also referred to as enantiomers, may have different pharmacokinetic, pharmacodynamic, and toxicological effects. Thus, pharmaceutical manufacturers and authorities are increasingly interested in the approval of enantiopure drugs. However, the isomeric purity and the limits for isomeric impurities have to be specified applying enantioselective analytical methods, such as capillary electrophoresis. The separation of enantiomers in capillary electrophoresis may be improved by the addition of ionic liquids to the background electrolyte. The aim of this work was to investigate the influence of different separation conditions on the enantioseparation of phenethylamines in background electrolytes containing ionic liquids based on tetrabutylammonium cations. Best chiral separations were achieved at acidic pH values using phosphate buffers containing 125 mmol/L tetrabutylammonium based salts. Different reasons explaining enhanced enantioseparations in buffers containing ionic liquids were found. First, due to an improvement of the cyclodextrin solubility, the addition of ionic liquids to the background electrolyte enables the use of higher concentrations of these chiral selector. Furthermore, the adsorption of tetrabutylammonium cations to the negatively charged capillary surface results in a reduction of the electroosmotic flow. Hence, the resulting prolongation of migration times leads to a longer period of time for the separation of temporarily formed diastereomeric analyte cyclodextrin complexes, which yields improved enantioseparation. Additionally, due to a decrease of the adsorption of positively charged phenethylamine analyte molecules to capillary surface silanol groups, the adsorption of ionic liquid cations inhibits peak broadening. A further reason explaining an enhanced enantioseparation by the addition of ionic liquids to the background electrolyte is a competition between tetrabutylammonium cations and analyte enantiomers for the inclusion into cyclodextrin cavities. Furthermore, the influence of different chiral counterions, combined with tetrabutylammonium cations, on the enantioseparation of phenethylamines was investigated. Solely anions based on the basic proteinogenic amino acids L lysine and L arginine yielded chiral separation results superior to those achieved using achiral tetrabutylammonium chloride as background electrolyte additive. Especially the application of tetrabutylammonium L argininate gave very good enantioseparations of all investigated ephedrine derivatives, which might be explained by the ability of L arginine to affect the formation of complexes between analytes and cyclodextrins. Besides the investigation of the influence of ionic liquids on the enantioseparation, complexes between phenethylamine enantiomers and β cyclodextrin derivatives were characterized by affinity capillary electrophoresis. The binding constants between analyte enantiomers and cyclodextrins and the electrophoretic mobilities of the temporarily formed complexes were determined and compared to the observed chiral resolution values. While neither the calculated binding constants nor their differences correlated with the quality of the enantioseparation, a strong correlation between the differences of the electrophoretic mobilities of the complexes and the chiral resolution values was found.}, subject = {Kapillarelektrophorese}, language = {en} } @phdthesis{Berninger2019, author = {Berninger, Michael}, title = {Development of Novel Quinolone Amides Against the African Sleeping Sickness - A Fluorine Walk}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-176428}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2019}, abstract = {In recent years the transmission of the Human African Trypanosomiasis could be significantly reduced. The reported cases in 2016 reached a historic low level of 2184 cases and these achievements can be ascribed to intense control and surveillance programmes.118 However, most of the reported cases (>1000 in 2015) occurred in the Democratic Republic of the Congo and thus, need to be treated adequately. In particular, when the parasites have traversed the blood-brain barrier (BBB), treatment proved to be even more difficult. In addition, the number of cases always came in waves due to many reasons, e.g., development of resistances. Thus, it can be expected from experiences of the past that the number of cases will increase again. Hence, novel chemical entities are desperately needed in order to overcome the drawbacks which are associated with the current treatment options. Our drug discovery approach included an initial drug repurposing strategy combined with a phenotypic screening. S. Niedermeier found novel active compounds derived from commercial fluoroquinolones. The most promising hit compound was further developed by G. Hiltensperger resulting in the lead quinolone amide GHQ168 (IC50 = 0.047 µM). This doctoral thesis is about new insights into the SAR of the quinolone amides and the enhancement of the lead compound. Special consideration was given to the fluorine atom in the quinolone amides and how certain fluorine substitution patterns influence the antitrypanosomal activity, physicochemical properties and pharmacokinetics (i.e. 'fluorine walk'). Moreover, the ability of the compound class crossing the BBB should be investigated. This feature is inevitable necessary in order to potentially treat African sleeping sickness stage II. The Gould-Jacobs protocol was predominantly used for the synthesis of the quinolone core. Since former SAR studies mainly concentrated on the variation in positions 1, 3 and 7, quinolone scaffolds (2a-i) with diverse substitution patterns regarding positions 5, 6, 7 and 8 were synthesised in this thesis. The resulting quinolone amides were evaluated for their antitrypanosomal activity. Voluminous residues in position C-5 resulted in diminished activities (compounds 13, 16 and 18) and solely small-sized moieties were tolerated. In particular the fluorine atom in position 5 revealed beneficial trypanocidal effects as shown for compounds 6 (IC50 = 0.05 µM), 8 (IC50 = 0.04 µM), and 24 (IC50 = 0.02 µM). Furthermore, having fluorine only in position 5 of the quinolone core could considerably reduce the cytotoxic effects (CC50 >100 µM, SI = >2000 for 6). Hence, the 5-fluoro-substituted quinolone amides were considered superior to GHQ168. Regarding the C-6 position all other moieties (e.g., H in 9, OCH3 in 10, CF3 in 12) except of a fluorine atom decreased the activity against Trypanosoma brucei brucei. A double fluorination in C-6 and C-8 was not beneficial (IC50 = 0.06 µM for 7) and a single fluorine atom in C-8 even showed a negative effect (IC50 = 0.79 µM for 5). The logP value is considered a surrogate parameter for lipophlicity and thus, affecting permeability and solubility processes. In particular the fluorine atom influences the lipophilicity due to versatile effects: Lipophilicity is increased by additional fluorine atoms on aromatic rings (7, 23) and reduced by fluorine atoms at an alkyl chain (49), respectively. Additionally, the 5-fluoro-substituted quinolone amides (6, 8, and 24) could prove the contrary effect of decreasing lipophilicity when the aromatic fluorine substituent is in vicinity to a carbonyl group. For the most promising drug candidates 6, 23, and 24 the respective metabolites and the metabolic turnover were investigated by C. Erk. In comparison to GHQ168 the hydroxylation of the benzylamide was prevented by the para-fluorine atom. Hence, half-life was extended for compound 23 (t1/2 = 6.4 h) and N-desalkylation was the predominant pathway. Moreover, the respective fluorine substitution pattern of the quinolone core affected the metabolism of compound 6. The 5-fluoro-substituted quinolone amide was less prone for biotransformation (t1/2 = 7.2 h) and half-life could even be further prolonged for compound 24 (t1/2 = 7.7 h). Due to the most appropriate safety profile of compound 6, this particular drug candidate was considered for in vivo study. Its poor solubility made a direct intraperitoneal administration unfeasible. Thus, an amorphous solid dispersion of 6 was generated using the spray-drying method according to the previous protocol. Unfortunately, the required solubility for the predicted in vivo study was not achieved. Furthermore, the compound class of the quinolone amide was evaluated for its ability for brain penetration. The methanesulfonyl precursor 48 was synthesised and subsequently radiofluorinated in the group of Prof. Dr. Samnick (Department of Nuclear Medicine, University Hospital of W{\"u}rzburg). The labelled compound [18F]49 was administered to mice, and its distribution throughout the body was analysed using positron emission tomography and autoradiography, respectively. The autoradiography of the murine brains revealed medium to high concentrations of [18F]49. Therefore, the quinolone amides are generally suitable for treating Human African Trypanosomiasis stage II. A scaffold hopping approach was performed starting from the quinolone amides and concluding with the compound class of pyrazoloquinolin-3-ones. The intramolecular hydrogen bond between the sec. amide and the C-4 carbonyl moiety was replaced by a covalent bond. The two compound classes were comparable regarding the antitrypanosomal activity to some degree (IC50 = 7.9 µM (EK02) vs. 6.37 µM (53a)). However, a final evaluation of 59 was not possible due to poor solubility.}, subject = {Trypanosomiase}, language = {en} } @phdthesis{Zilker2019, author = {Zilker, Markus}, title = {The stability of finished pharmaceutical products and drug substances beyond their labeled expiry dates}, doi = {10.25972/OPUS-18069}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-180695}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2019}, abstract = {Upon approval of a drug, the stability of the API and the FPP has to be studied intensively because it determines the shelf-life. If a drug is found to be stable, the expiry date is arbitrary set to five years at the maximum, if a drug tends to undergo degradation, the expiry date is set shorter. The drug product must comply with predefined specifications in accordance with the ICH guidelines Q6A and Q6B during its entire market life. The content of the active substance is required to be within a specification of 95-105\% of its labeled claim until expiry corresponding to the ICH guideline Q1A(R2). However, there is little or scattered literature information addressing the stability of drug products beyond their expiry dates. The objective of this thesis was to study and assess the long-term stability of a collection involving numerous pure drug substances and ampoules manufactured in the 20th century. The content and the impurity profile were examined by means of appropriate analytical methods, mainly using liquid chromatography. The results were compared to data being available in the literature. Assessing the stability regarding the dosage form and the affiliation of the drug class was conducted. The experimental studies comprise the examination of 50 drug substances manufactured 20-30 years ago and 14 long expired ampoules which were older than 40 years in the time of analysis, exceeding many times the maximum shelf life of five years. For investigation of the solid drug substances, pharmacopoeial methods were applied as far as possible. Indeed, results of the study showed that 44 tested substances still complied with the specification of the Ph. Eur. with regard to the content and impurity profile, even after more than two decades of storage. For analysis of the injection solutions, HPLC-UV and HPLC-ESI/MS techniques were applied, commonly based on liquid chromatography methods of the Ph. Eur. for determination of related substances. Each method was further validated for its application to ensure accurate API quantification corresponding to ICH Q2(R1). Quite a few ampoules were identified to show surprisingly high stability. In spite of their age of 53-72 years, APIs such as caffeine, etilefrine, synephrine, metamizole sodium, furosemide, and sodium salicylate complied with the specified content that is valid nowadays, respectively. Nevertheless, typical degradation reaction, e.g. hydrolysis, oxidation, or isomerization, was observed in all remaining ampoules. Various degrees of hydrolysis were revealed for scopolamine, procaine, and adenosine triphosphate, the contents were decreased to 71\%, 70\%, and 15\% of the declared concentrations, respectively. In the epinephrine and dipyridamole ampoules, oxidative degradation has been occurred, finding respective API contents of more or less 70\%. For dihydroergotamine, excessive decomposition by epimerization was observed, resulting in an API content of 21\% and degradation by isomerization was found in lobeline, still containing 64\% of the labeled claim. In conclusion, supported by the data of the present studies and the literature, defining and authorizing a longer shelf-life may be applicable to numerous pharmaceuticals which should be considered by pharmaceutical manufacturers and regulatory authorities, if justified based on stability studies. A general extension of the shelf-lives of drug products and the abolishment or extension of the maximum shelf-life limit of five years would prevent disposing of still potent medications and save a lot of money to the entire health care system.}, subject = {Stabilit{\"a}t}, language = {en} } @phdthesis{Kraehnke2019, author = {Kr{\"a}hnke, Martin}, title = {Chondrogenic differentiation of bone marrow-derived stromal cells in pellet culture and silk scaffolds for cartilage engineering - Effects of different growth factors and hypoxic conditions}, doi = {10.25972/OPUS-19299}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-192999}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2019}, abstract = {Articular cartilage lesions that occur upon intensive sport, trauma or degenerative disease represent a severe therapeutic problem. At present, osteoarthritis is the most common joint disease worldwide, affecting around 10\% of men and 18\% of women over 60 years of age (302). The poor self-regeneration capacity of cartilage and the lack of efficient therapeutic treatment options to regenerate durable articular cartilage tissue, provide the rationale for the development of new treatment options based on cartilage tissue engineering approaches (281). The integrated use of cells, biomaterials and growth factors to guide tissue development has the potential to provide functional substitutes of lost or damaged tissues (2,3). For the regeneration of cartilage, the availability of mesenchymal stromal cells (MSCs) or their recruitment into the defect site is fundamental (281). Due to their high proliferation capacity, the possibility to differentiate into chondrocytes and their potential to attract other progenitor cells into the defect site, bone marrow-derived mesenchymal stromal cells (BMSCs) are still regarded as an attractive cell source for cartilage tissue engineering (80). However, in order to successfully engineer cartilage tissue, a better understanding of basic principles of developmental processes and microenvironmental cues that guide chondrogenesis is required.}, subject = {Hypoxie}, language = {en} } @phdthesis{Wistlich2019, author = {Wistlich, Laura}, title = {NCO-sP(EO-stat-PO) as functional additive for biomaterials' development}, doi = {10.25972/OPUS-17836}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-178365}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2019}, abstract = {The aim of this thesis was the application of the functional prepolymer NCO-sP(EO-stat-PO) for the development of new biomaterials. First, the influence of the star-shaped polymers on the mechanical properties of biocements and bone adhesives was investigated. 3-armed star-shaped macromers were used as an additive for a mineral bone cement, and the influence on the mechanical properties was studied. Additionally, a previously developed bone adhesive was examined regarding cytocompatibility. The second topic was the examination of novel functionalization steps which were performed on the surface of electrospun fibers modified with NCO-sP(EO-stat-PO). This established method of functionalizing electrospun meshes was advanced regarding the modification with proteins which was then demonstrated in a biological application. Two different kinds of antibodies were immobilized on the fiber surface in a consecutive manner and the influence of these proteins on the cell behavior was investigated. The final topic involved the quantification of surface-bound peptide sequences. By functionalization of the peptides with the UV-reactive molecule 2-mercaptopyridine it was possible to quantify this compound via UV measurements by cleavage of disulfide bridges and indirectly draw conclusions about the number of immobilized peptides. In the field of mineral biocements and bone adhesives, NCO-sP(EO-stat-PO) was able to influence the setting behavior and mechanical performance of mineral bone cements based on calcium phosphate chemistry. The addition of NCO-sP(EO-stat-PO) resulted in a pseudo-ductile fracture behavior due to the formation of a hydrogel network in the cement, which was then mineralized by nanosized hydroxyapatite crystals following cement setting. Accordingly, a commercially available aluminum silicate cement from civil engineering could be modified. In addition, it could be shown that the use of NCO-sP(EO-stat-PO) is beneficial for adjusting specific material properties of bone adhesives. Here, the crosslinking behavior of the prepolymer in an aqueous medium was exploited to form an interpenetrating network (IPN) together with a photochemically curing poly(ethylene glycol) dimethacrylate (PEGDMA) matrix. This could be used for the development of a bone adhesive with an improved adhesion to bone in a wet environment. The developed bone adhesive was further investigated in terms of possible influences of the initiator systems. In addition, the material system was tested for cytocompatibility by using different cell lines. Moreover, the preparation of electrospun fiber meshes via solution electrospinning consisting of poly(lactide-co-glycolide) (PLGA) as a backbone polymer and NCO-sP(EO-stat-PO) as functional additive is an established method for the application of the meshes as a replacement of the native extracellular matrix (ECM). In general, these fibers reveal diameters in the nanometer range, are protein and cell repellent due to the hydrophilic properties of the prepolymer and show a specific biofunctionalization by immobilization of peptide sequences. Here, the isocyanate groups presented on the fiber surface after electrospinning were used to carry out various functionalization steps, while retaining the properties of protein and cell repellency. The modification of the electrospun fibers involved the immobilization of analogs or antagonists of tumor necrosis factor (TNF) and the indirect detection of these by interaction with a light-producing enzyme. Here, a multimodal modification of the fiber surface with RGD to mediate cell adhesion and two different antibodies could be achieved. After culturing the cell line HT1080, the pro- or anti-inflammatory response of cells could be detected by IL-8 specific ELISA measurements. Furthermore, the quantification of molecules on the surface of electrospun fibers was investigated. It was tested whether the detection by means of super-resolution microscopy would be possible. Therefore, experiments were performed with short amino acid sequences such as RGD for quantification by fluorescence microscopy. Based on earlier results, in which a UV-spectrometrically active molecule was used to detect the quantification of RGD, it was shown that short peptides can also be quantified in a small scale on flat functional substrates (2D) such as NCO-sP(EO-stat-PO) hydrogel coatings, and modified electrospun fibers produced from PLGA and NCO-sP(EO-stat-PO) (3D). In addition, a collagen sequence was used to prove that a successful quantification can be carried out as well for longer peptide chains. These studies have revealed that NCO-sP(EO-stat-PO) can serve as a functional additive for many applications and should be considered for further studies on the development of novel biomaterials. The rapid crosslinking reaction, the resulting hydrogel formation and the biocompatibility are to be mentioned as positive properties, which makes the prepolymer interesting for future applications.}, subject = {Sternpolymere}, language = {en} } @phdthesis{Gutmann2019, author = {Gutmann, Marcus}, title = {Functionalization of cells, extracellular matrix components and proteins for therapeutic application}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-170602}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2019}, abstract = {Glycosylation is a biochemical process leading to the formation of glycoconjugates by linking glycans (carbohydrates) to proteins, lipids and various small molecules. The glycans are formed by one or more monosaccharides that are covalently attached, thus offering a broad variety depending on their composition, site of glycan linkage, length and ramification. This special nature provides an exceptional and fine tunable possibility in fields of information transfer, recognition, stability and pharmacokinetic. Due to their intra- and extracellular omnipresence, glycans fulfill an essential role in the regulation of different endogenous processes (e.g. hormone action, immune surveillance, inflammatory response) and act as a key element for maintenance of homeostasis. The strategy of metabolic glycoengineering enables the integration of structural similar but chemically modified monosaccharide building blocks into the natural given glycosylation pathways, thereby anchoring them in the carbohydrate architecture of de novo synthesized glycoconjugates. The available unnatural sugar molecules which are similar to endogenous sugar molecules show minimal perturbation in cell function and - based on their multitude functional groups - offer the potential of side directed coupling with a target substance/structure as well as the development of new biological properties. The chemical-enzymatic strategy of glycoengineering provides a valuable complement to genetic approaches. This thesis primarily focuses on potential fields of application for glycoengineering and its further use in clinic and research. The last section of this work outlines a genetic approach, using special Escherichia coli systems, to integrate chemically tunable amino acids into the biosynthetic pathway of proteins, enabling specific and site-directed coupling with target substances. With the genetic information of the methanogen archaea, Methanosarcina barkeri, the E. coli. system is able to insert a further amino acid, the pyrrolysine, at the ribosomal site during translation of the protein. The natural stop-codon UAG (amber codon) is used for this newly obtained proteinogenic amino acid. Chapter I describes two systems for the integration of chemically tunable monosaccharides and presents methods for characterizing these systems. Moreover, it gives a general overview of the structure as well as intended use of glycans and illustrates different glycosylation pathways. Furthermore, the strategy of metabolic glycoengineering is demonstrated. In this context, the structure of basic building blocks and the epimerization of monosaccharides during their metabolic fate are discussed. Chapter II translates the concept of metabolic glycoengineering to the extracellular network produced by fibroblasts. The incorporation of chemically modified sugar components in the matrix provides an innovative, elegant and biocompatible method for site-directed coupling of target substances. Resident cells, which are involved in the de novo synthesis of matrices, as well as isolated matrices were characterized and compared to unmodified resident cells and matrices. The natural capacity of the matrix can be extended by metabolic glycoengineering and enables the selective immobilization of a variety of therapeutic substances by combining enzymatic and bioorthogonal reaction strategies. This approach expands the natural ability of extracellular matrix (ECM), like the storage of specific growth factors and the recruitment of surface receptors along with synergistic effects of bound substances. By the selection of the cell type, the production of a wide range of different matrices is possible. Chapter III focuses on the target-oriented modification of cell surface membranes of living fibroblast and human embryonic kidney cells. Chemically modified monosaccharides are inserted by means of metabolic glycoengineering and are then presented on the cell surface. These monosaccharides can later be covalently coupled, by "strain promoted azide-alkyne cycloaddition" (SPAAC) and/or "copper(I)-catalyzed azide-alkyne cycloaddition" (CuAAC), to the target substance. Due to the toxicity of the copper catalysator in the CuAAC, cytotoxicity analyses were conducted to determine the in vivo tolerable range for the use of CuAAC on living cell systems. Finally, the efficacy of both bioorthogonal reactions was compared. Chapter IV outlines two versatile carrier - spacer - payload delivery systems based on an enzymatic cleavable linker, triggered by disease associated protease. In the selection of carrier systems (i) polyethylene glycol (PEG), a well-studied, Food and Drug Administration approved substance and very common tool to increase the pharmacokinetic properties of therapeutic agents, was chosen as a carrier for non-targeting systems and (ii) Revacept, a human glycoprotein VI antibody, was chosen as a carrier for targeting systems. The protease sensitive cleavable linker was genetically inserted into the N-terminal region of fibroblast growth factor 2 (FGF-2) without jeopardizing protein activity. By exchanging the protease sensitive sequence or the therapeutic payload, both systems represent a promising and adaptable approach for establishing therapeutic systems with bioresponsive release, tailored to pre-existing conditions. In summary, by site-specific functionalization of various delivery platforms, this thesis establishes an essential cornerstone for promising strategies advancing clinical application. The outlined platforms ensure high flexibility due to exchanging single or multiple elements of the system, individually tailoring them to the respective disease or target site.}, subject = {Glykosylierung}, language = {en} } @phdthesis{Lieberherr2019, author = {Lieberherr, Christina}, title = {Untersuchung der Wirkung potentieller Inhibitoren der Masernvirus-Infektion}, doi = {10.25972/OPUS-17675}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-176752}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2019}, abstract = {Die Infektion mit dem Masernvirus (MV) stellt weltweit immer noch ein großes Problem dar. Trotz des vorhandenen Lebendimpfstoffs, der eine Erkrankung sicher zu verhindern vermag, haben nicht nur die Entwicklungsl{\"a}nder, in denen ein fl{\"a}chendeckender Impfschutz schwieriger zu erreichen ist, mit der Erkrankung und ihren Komplikationen zu k{\"a}mpfen. Hat sich die Erkrankung klinisch manifestiert gibt es keine kausalen Therapiem{\"o}glichkeiten und es kann nur noch symptomatisch behandelt werden. Dies ist v.a. auch in Hinblick auf die schweren Komplikationen der Maserninfektion von Bedeutung. Bei Erstkontakt mit dem Masernvirus ist die Suszeptibilit{\"a}t nicht geimpfter Menschen sehr hoch. Das bedeutet, dass es in 95-98 \% der F{\"a}lle nach einer Infektion mit dem Masernvirus auch zum klinischen Bild der Masern kommt, unabh{\"a}ngig von Alter und Geschlecht. Das Ziel dieser Arbeit war es daher, potentielle Hemmstoffe der Maserninfektion auf ihre Wirkung zu testen und zu verstehen, wo im Infektions- und Replikationszyklus des MV sie eingreifen. Es wurden eine Reihe Substanzen mit potentiell-inhibitorischen Eigenschaften in Infektions-Hemmtests und im Zytotoxizit{\"a}tstest untersucht, von denen im Anschluss die drei besten Inhibitoren (JK80, QD6-8 und Droseron) weiter untersucht wurden. JK80 und QD6-8 waren beide mit IC50-Werten um 30 µM und SI-Werten von {\"u}ber 2 nur m{\"a}ßig spezifisch antiviral wirksam. W{\"a}hrend JK80 vermutlich den Eintritt des MV in die Zellen verhindert, hemmt QD6-8 die intrazellul{\"a}re Virusreplikation und w{\"a}re im Hinblick auf die Entwicklung neuartiger, spezifischer Medikamente gegen die Maserninfektion von grossem Interesse. Eine Zielmolek{\"u}lanalyse der Substanz und die Testung anderer Derivate k{\"o}nnten Aufschluss dar{\"u}ber geben, wie Substanzen aussehen m{\"u}ssten, die eine spezifische Hemmung der intrazellul{\"a}ren Replikation bewirken k{\"o}nnen. Der Naturstoff Droseron k{\"o}nnte mit einer spezifischen Hemmung (IC50 ca. 10 µM; SIWert 6 im Fluoreszenzreader, bzw. IC50 ca. 2 µM; SI-Wert 30 in der Titration) eine m{\"o}gliche Leitsubstanz f{\"u}r einen neuen MV-Inhibitor darstellen. Allerdings waren alle bisher getesteten Droseron-Derivate entweder weniger inhibitorisch wirksam oder deutlich zytotoxischer als Droseron selbst. Die Ergebnisse der Infektionshemmversuche mit Zugabe von Droseron vor, w{\"a}hrend oder nach der Infektion mit MV sprechen daf{\"u}r, dass Droseron den Eintritt des Virus in die Zelle st{\"o}rt.}, subject = {Masernvirus}, language = {de} } @phdthesis{Theiss2019, author = {Theiss, Christiane}, title = {Qualitative Charakterisierung polydisperser Macrogole sowie strukturell verwandter Hilfsstoffe mittels HPLC-CAD}, doi = {10.25972/OPUS-17927}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-179274}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2019}, abstract = {The class of macrogols and macrogol-based excipients, i.e. macrogol fatty alcohol ethers, macrogol fatty acid esters, and polysorbates, plays an important role in modern galenic formulations. Formerly used as simple emulsifiers, they are nowadays utilized in fields such as targeted drug release to increase bioavailability, and as solubilizers for complex systems. For these multifaceted applications, and regarding the polydisperse structures of the macrogols, a reproducible and significant analytical procedure is required. For the characterization of excipients, the European Pharmacopoeia (Ph. Eur.) provides some compendial protocols which are able to describe the number of functional groups present in the substance. Some examples of these bulk parameters are the hydroxyl value, the iodine value, the peroxide value, or the acid value. Thus, these bulk parameters allow an overview of the average molar weight or possible degradation processes (e.g. autoxidation), but they provide no further information about the polymeric distribution which can heavily depend on the manufacturing process. Furthermore, bulk parameter investigations are very time-consuming and prone to errors due to their stringent reaction processes and numerous reaction steps. Since several years, the HPLC has been the gold standard of pharmaceutical analytics particularly due to the fact of automation. Coupled to UV detection, it offers the opportunity for a quick, easy, and robust analysis for many drugs. In the field of excipients, the development progress of HPLC-analysis is much slower due to the fact that most excipients lack a UV-chromophore. The application of the highly sensitive mass spectrometry would be eligible for detection but is rather complex and expensive. However, the development of the aerosol-based detectors such as the ELSD (evaporative light scattering detection), the CAD (charged aerosol detection), and the NQADTM (nano quantity aerosol detection) enables the application of HPLC for analyzing non-chromophoric substances. This work aimed to develop a generic HPLC-CAD method to analyze a wide range of macrogols and macrogol-based excipients. The separation was performed on a C18-column. A gradient method was developed based upon several linear gradient steps in order to be able to separate the different chain lengths. The mobile phases were water and acetonitrile, respectively, to which 0.1\% formic acid was added. Macrogols in the average size range of PEG 300 to PEG 3000 were separated with acceptable resolution. The separation results were verified by mass spectrometry for PEG 300 - 1500. Five saturated and two non-saturated fatty acids, as well as two fatty alcohols of different chain lengths were successfully separated. 13 macrogol-based excipients were analyzed with the developed method and separated successfully. The macrogol fatty alcohol ethers, macrogol stearates, and polysorbates were separated to sufficient extent to analyze the polymeric distribution. The free PEGs in the excipients were separated and identified. Based on these free PEGs, different manufactural processes could be determined. Depending on the average chain lengths of the processed PEGs, the free fatty acids or alcohols could be identified and separated from the esters or ethers, respectively. For the smaller average chain lengths, the free fatty acids and alcohols coeluted with the esters and ethers. Macrogol glycerol hydroxy stearate (Cremophor® RH40) was separated into its components except for the linear monoesters which partially coeluted with the free PEGs, and the glycerol triesters which showed effects of size exclusion. The developed method was also used for stability tests of the non-saturated fatty acids, i.e. oleic and linoleic acid. Here, the fatty acid solutions were chemically (hydrogen peroxide) and thermally (60 °C) stressed and analyzed after different time spans. A time and temperature dependent degradation was observed. An assignment of some degradation products was performed by determining the m/z values with mass spectrometry. The method proved to be capable of separating the degradation products of the main substance and allows to estimate the dimension of degradational processes and partly identify the structures of the degradational products. In general, the provided method offers a good basis for analyzing and characterizing a wide field of substance classes. It provides an extension of bulk parameters (e.g. hydroxyl value) with a reduction of analytical effort. It offers a good starting point for more specific observations such as long-term stability or other related substance classes.}, subject = {HPLC}, language = {de} } @phdthesis{Dirimanov2019, author = {Dirimanov, Stoyan Dinkov}, title = {Molecular Effects of Polyphenols in Experimental Type 2 Diabetes Mellitus and Metabolic Syndrome}, doi = {10.25972/OPUS-18570}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-185701}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2019}, abstract = {The growing prevalence of type 2 diabetes mellitus (T2DM) demands novel therapeutic and adjuvant strategies. Polyphenols (PPs) are plant secondary metabolites. Epidemiological studies demonstrate an inverse relationship between their increased intake and the risk of development of T2DM and cardiovascular complications. However, the PPs' mechanism of action remains largely unknown. The present work aimed to expand knowledge regarding the effects of PPs on diabetes relevant molecular targets. Pycnogenol® (PYC) is a standardized pine bark extract which consists of oligomeric and monomeric PPs. Its anti-diabetic effects have been demonstrated in clinical trials. As a part of a human study involving 20 healthy volunteers, the extract's effects on dipeptidyl peptidase IV (DPP IV) were investigated. This protease terminates the insulin secretagogue action of incretins. Its inhibition is a promising strategy in T2DM treatment. This study uncovered that PYC-intake of 100 mg daily over 14 days statistically significantly reduced DPP IV serum concentrations by 8.2 \% (n= 38, p= 0.032). Contrary to expectations, this decrease was not paralleled by a reduction in the serum DPP IV enzymatic activity. To the best of our knowledge, the present study was the first investigating the effects of PPs on DPP IV serum concentrations and activities in humans. The finding that PYC is capable of reducing DPP IV serum concentrations might be important with regard to diabetes, where DPP IV levels are increased. Screenings for PPs' in vitro effects on DPP IV activity were performed employing a purified enzyme. The effects of tested PPs (among which PYC ingredients) at a physiologically relevant concentration of 5 µM were weak (< 10 \%) and too small compared to the reference compound sitagliptin, and thus not likely to be clinically relevant. This result is in discordance with some published data, but consistent with the outcome from the present human study. In addition, fluorescence interactions with the experimental setup were registered: under certain conditions urolithin B exhibited an autofluorescence which might mask eventual inhibitory activity. Quercetin quenched the fluorescence slightly which might contribute to false positive results. No statistically significant effects of selected constituents and metabolites of PYC on the total DPP IV protein expression were observed in 3T3-L1 adipocytes. Thus, the lower DPP IV in vivo concentrations after intake of PYC cannot be explained with down-regulation of the DPP IV expression in adipocytes. Akt kinase is responsible for the transmission of insulin signals and its dysregulation is related to insulin resistance and plays an important role in development of cardiovascular complications in T2DM. Thus, the modulation of the phosphorylation status of endothelial Akt-kinase, respectively its activity, might be a promising strategy in the management of these pathologies. This work aimed to uncover the effects of PPs from different structural subclasses on Akt-phosphorylation (pAkt) in endothelial cells (Ea.hy926). Short-term effects (5 - 30 min) were investigated at a concentration of 10 µM. In a pilot study two model PPs induced a moderate, but reproducible inhibition of pAkt Ser473 of 52.37 ± 21.01 \% (quercetin; p= 0.006, n= 3) and 37.79 ± 7.14 \% (resveratrol; p= 0.021, n= 4) compared to the negative control. A primary screening with Western blot analysis investigated the effects of eight compounds from different subclasses on pAkt Ser473 and Thr308 to reveal whether the observed inhibition PPs a group effect or specific to certain compounds. In addition to resveratrol and quercetin, statistically significant inhibitions of pAkt Ser473 were induced by luteolin (29.96 ± 11.06 \%, p< 0.01, n= 6) and apigenin (22.57 ± 10.30 \%, p< 0.01, n= 6). In contrast, genistein, 3,4,5-trimethoxystilbene, taxifolin and (+)-catechin caused no inhibition. A strong positive and statistically significant correlation between the mean inhibitory effects of the tested PPs on both Akt-residues Ser473 and Thr308 (r= 0.9478, p= 0.0003) was determined. A comprehensive secondary screening via ELISA involving 44 compounds from nine structural groups quantified the effects of PPs on pAkt Ser473 to uncover potential structure-activity features. The most potent inhibitors were luteolin (44.31 ± 17.95 \%), quercetin (35.71 ± 8.33 \%), urolithin A (35.28 ± 11.80 \%), apigenin (31.79 ± 6.16 \%), fisetin (28.09 ± 9.09 \%), and resveratrol (26.04 ± 5.58 \%). These effects were statistically significant (p< 0.01, n= 3 to 6). Further lead structure optimization might be based on the fact that the effects of luteolin and resveratrol also differed statistically significantly from each other (p= 0.008). To the best of our knowledge, the present study is the first to compare quantitatively the short term effects of PPs from different subclasses on pAkt in endothelial cells. Basic structure-activity relationships revealed that for flavones and flavonols the presence of a C2=C3 double bond (ring C) was essential for inhibitory activity and hydroxylation on the m- and p- positions in the ring B contributed to it. For stilbenoids, three free OH-groups appeared to be optimal. The comparison of the inhibitory potentials of ellagic acid and its microbial metabolites showed that urolithin A was statistically significantly more effective than its progenitor compound. Despite their structural similarities, the only active compound among all urolithins tested was urolithin A, hydroxylated at the C3 and C8 positions. This suggested a specific effect for urolithin A. Based on the common structural determinants and molecular geometry of the most active PPs a pharmacophore model regarding Akt-inhibition was proposed. In summary, the effects of a wide variety of PPs from diverse structural subclasses on the in vitro phosphorylation of endothelial Akt were quantitatively analyzed for the first time, the effects of previously undescribed compounds were determined and structure activity relationships were elucidated. The inhibitory potential of individual PPs might be beneficial in cases of sustained over-activation of Akt-kinase and its substrates such as S6 kinase as reported for certain T2DM-related pathological states, such as insulin resistance, endothelial dysfunction, excessive angiogenesis, vascular calcification, and insulin triggered DNA-damage. The results of the present work suggest potential molecular mechanisms of action of PP involving Akt-inhibition and DPP IV-down-regulation and thus contribute to the understanding of anti-diabetic effects of these compounds on the molecular level.}, subject = {Polyphenole}, language = {en} } @phdthesis{Munz2019, author = {Munz, Martin Reinhold}, title = {Individualization of drug therapy considering pharmacokinetic and clinical factors}, doi = {10.25972/OPUS-17339}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-173396}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2019}, abstract = {In the „Position Paper of the Division of Clinical Pharmacy of the German Pharmaceutical Society (DPhG)" clinical pharmacy is defined as the science and practice of the rational use of drugs1, which includes the individualization of drug therapy. Clinical pharmacists therefore need a profound knowledge of the pharmacokinetic properties of relevant drugs, and clinical factors that are influencing these properties. Against the background of individualizing drug therapy, pharmacokinetic and clinical factors are studied in this thesis. In order to obtain an overview of the existing data on the pharmacokinetics of imipenem / cilastatin and meropenem in critically ill patients, a literature review for each of these carbapenem antibiotics was performed. These reviews included studies in critically ill patients as well as studies in healthy volunteers. While the reported results of studies in healthy volunteers had a small variability, studies in critically ill patients show significant differences in the resulting pharmacokinetics. These differences were not only between, but also within these studies, resulting in a high variability of the pharmacokinetic parameters of the carbapenems in critically ill patients. Furthermore, the results of studies in critically ill patients indicate that clinical factors and in particular renal function have different effects on the pharmacokinetics of imipenem and cilastatin. A therapeutic drug monitoring (TDM) program for antibiotics was initiated in an intensive care unit. The calculation of the pharmacokinetics of imipenem / cilastatin and meropenem was carried out with a population pharmacokinetic approach (POP-PK) and in addition with a non-compartmental approach (NCA). The POP-PK analysis showed that the pharmacokinetics of imipenem and cilastatin could be described adequately with a 1-compartment model. The resulting mean total body clearance (CL) of imipenem and cilastatin was 11.6 L/h (4.24 to 27.5) and 6.14 L/h (0.520 to 26.6 L/h). The nonrenal clearance was estimated to be 5.30 L / h (24.9\% CV) for imipenem and 0.138 L / h (33.3\% CV) for cilastatin. The results of the NCA were in good agreement with the results of the POP-PK approach, as the NCA resulted in an imipenem clearance of 15.5 ± 7.3 L / hr and cilastatin clearance of 10.1 ± 9.9 L / h. The individual clearances resulting from the different pharmacokinetic approaches were in good correlation showing correlation coefficients (r) of 0.882 (p <0.001) and 0.908 (p <0.001) for imipenem and cilastatin. In summary, this study identified and quantified significant differences between the individual clearance mechanisms of imipenem and cilastatin. This is particularly true for patients with impaired renal function and sepsis. As imipenem / cilastatin is only available in a fixed dose combination, those patients might be treated inadequately with this combination. The great variability in the pharmacokinetics of imipenem and cilastatin in septic patients underscores the importance of a TDM program of both substances. For meropenem, a PK/PD model was developed that predicts the concentration gradients of meropenem, serum creatinine, C-reactive protein and procalcitonin simultaneously. A non-linear relationship between the clearance of creatinine and meropenem was identified and the resulting equation for the calculation of the total body clearance of meropenem (for a 70 kg patient) was: 0.480 L/h + 9.86 L/h. (CLCR/6L/h)0.593, with 0.480 L/h representing the nonrenal clearance of meropenem. The resulting mean meropenem clearance of the NCA was 11.9 ± 8.7 L/h. The individual clearances resulting from the different pharmacokinetic approaches were poorly correlated showing a correlation coefficient (r) of 0.502 (p <0.001). In summary, this study showed a non-linear relationship of meropenem clearance and creatinine clearance. The model shows that the renal function may change rapidly and to a significant extent in patients with sepsis and septic shock, which in turn, underscores that creatinine concentrations are not in steady state in these patients. Conversely, dose adjustment based on creatinine values might lead to inappropriate therapy. This underlines the importance of a TDM program for meropenem in critically ill patients. The two most important considerations when choosing an antibiotic for the prophylaxis of postoperative bone infections are its activity against the whole spectrum of bacteria, which might be involved in bone infections, and its ability to penetrate bone tissue and thus to achieve concentrations above the minimum inhibitory concentration (MIC) of the corresponding pathogens. In order to gain information on this data, a study was conducted which investigated the pharmacokinetics of ampicillin / sulbactam in plasma, cortical and cancellous bone. Pharmacokinetic parameters in plasma were determined using NCA. The bone penetration represents the ratio of the concentration in the bone tissue to plasma concentration at the time of bone removal. The resulting half-life of ampicillin and sulbactam in plasma was 1.60  0.37 h and 1.70  0.42 h. The elimination of both substances was in a good correlation with creatinine clearance and resulted in correlation coefficients (r) of 0.729 (p = 0.003) for ampicillin and 0.699 (p = 0.005) for sulbactam. The mean clearance and the mean volume of distribution of ampicillin and sulbactam were 10.7  3.9 and 10.3  3.3 L/h, and 23.9  7.9 and 24.3  6.8 L. The mean concentrations of ampicillin in the cortical and cancellous bone were 6.60  4.22 and 10.15  7.40 µg/g, resulting in bone penetration ratios of 9.1  5.7 and 16.2  16.9 \%. For sulbactam the corresponding concentrations were 3.91  2.52 and 5.73  4.20 µg/g, resulting in bone penetration ratios of 10.6  6.3 and 17.5  16.1 \%. In summary, this study shows that the bone penetration of both substances is on average rather unsatisfactory and has a high variability, which can lead to inadequate bone concentrations for the prophylaxis of bone infections. One factor that could be identified for the penetration of both substances into cancellous bone was the period between the application of the drug and the removal of the bone. Therefore, a time interval between the administration of the antibiotic and the incision should be considered. Immunosuppression is a risk factor for the development of various malignancies, including hematologic diseases. While the relationship between the use of immunosuppressive therapy with methotrexate and the development of an Epstein-Barr virus (EBV) associated lymphoproliferative disease (LPD) has been well established, this connection is less evident for immunosuppressive therapy with azathioprine. The patient presented by us was immunosuppressed with azathioprine for autoimmune hepatitis. The development of an EBV-associated Hodgkin-like lymphoma under this immunosuppressive therapy and especially the regression of the lymphoma after cessation of azathioprine confirms the relationship between this immunosuppressant, EBV-infection and the development of Hodgkin-like lymphoma. Therefore, albeit in rare cases, azathioprine-related lymphomas may respond to mere cessation of immunosuppressive therapy without need for chemotherapy. Apart from viral infections, drugs are a major cause of acute liver failure. Due to the lack of specific symptoms or tests, it is difficult to diagnose a drug-induced liver injury. We report a case of a young patient in whom different antibiotics, the analgesic and antipyretic acetaminophen or a combination of these drugs may have led to DILI resulting in life-threatening ALF. Based on this case report, we describe a procedure to exclude non-drug related causes and discuss the hepatotoxic potential of the involved drugs in this case.}, subject = {Pharmakokinetik}, language = {en} } @phdthesis{Rasheed2019, author = {Rasheed, Huma}, title = {Development of simple and cost-effective High Performance Liquid Chromatography methods for quality control of essential beta-lactam antibiotics in low- and middle-income countries}, doi = {10.25972/OPUS-17721}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-177214}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2019}, abstract = {Assay and impurity profiling of the pharmaceuticals are the key routine quality control methods employed worldwide for which High Performance Liquid Chromatography (HPLC) is the most widely used technique. The ability to carry out these routine laboratory procedures in low- and middle- income countries (LMICs) need the methods to be based upon simple instruments manageable with moderate levels of personnel skill and costs involved. Simple, convenient, and cost effective reverse phase HPLC methods were developed using phosphate buffer and methanol as mobile phase with C18 column as stationary phase for the impurity profiling and assay of beta lactam antibiotics. Isocratic elution and UV detection was employed in these methods. Impurity profiling method was developed for coamoxiclav tablets and ceftriaxone bulk drug. The method for ceftriaxone included a supplementary method to quantify one of its known impurity (Impurity D of ceftriaxone). This method involved use of acetonitrile where as the two main methods were achieved on the targeted method design, described above. With the exception of impurity A of ceftriaxone, the methods developed can successfully quantify impurities to the concentration as low as ≤0.05\%, which is in accordance with the current guidelines for the impurity profiling of antibiotics issued by European Medicines Agency. As ensuring cost reduction was one of the key objectives of carrying out the method development exercise, in situ methods for the preparation of impurities were also identified and some new methods were introduced. The stability of beta lactam antibiotics and the choice of solvent were given due attention during the process of method development revealing information on the presence of new impurities. Deacetyl cefotaxime and 2-mercaptobenzathiazole were identified in this process as new impurities of ceftriaxone currently not listed under known impurities by United States Pharmacopoeia and European Pharmacopoeia. However, deacetyl cefotaxime is a known impurity of cefotaxime whereas the latter molecule is a degradation product of one of the synthesis impurities of ceftriaxone. This substance is reported to be carcinogenic and is resolved using the supplementary method developed for ceftriaxone, hence making its detection and quantification possible. A known inactive impurity of ceftriaxone (Impurity A, E-isomer of ceftriaxone) was` also shown to be produced by exposure to day light, thus warranting the light protection of the ceftriaxone solution, an information that is of critical importance in the clinical settings. A series of experimentation was carried out on the finished products of beta lactam antibiotics sampled from Pakistan and few other countries, to identify key quality issues in the samples. Though the limited sample size and convenient sampling did not provide results that could yield a decisive figure for the country status for prevalence of substandard and falsified medical products, but the experiments have clearly indicated that the problems in drug quality do exist and beta lactam antibiotics form a class of high-risk medicine with respect to surveillance for poor-quality medicines. Isolation of unknown impurities was also carried out along with the introduction of new and modified methods for preparation of impurities of beta-lactam antibiotics. In addition, detailed literature survey was carried out for understanding the complex problem of the poor-quality medicine, impact of poor quality antimicrobials on health care system and the magnitude of the problem at the global level. The country status of Pakistan regarding quality of medicines was recorded based upon the available documentary evidence. The current technologies and strategic options available for low- and middle-income countries in aiding fight for combating poor quality medicines was also laid down to design recommendations for Pakistan. A comprehensive review of the information technology tools used for identification and control of substandard and falsified medicines was also conducted.}, subject = {HPLC}, language = {en} } @article{ShahBulittaKinzigetal.2019, author = {Shah, Nirav R. and Bulitta, J{\"u}rgen B. and Kinzig, Martina and Landersdorfer, Cornelia B. and Jiao, Yuanyuan and Sutaria, Dhruvitkumar S. and Tao, Xun and H{\"o}hl, Rainer and Holzgrabe, Ulrike and Kees, Frieder and Stephan, Ulrich and S{\"o}rgel, Fritz}, title = {Novel population pharmacokinetic approach to explain the differences between cystic fibrosis patients and healthy volunteers via protein binding}, series = {Pharmaceutics}, volume = {11}, journal = {Pharmaceutics}, number = {6}, issn = {1999-4923}, doi = {10.3390/pharmaceutics11060286}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-196934}, year = {2019}, abstract = {The pharmacokinetics in patients with cystic fibrosis (CF) has long been thought to differ considerably from that in healthy volunteers. For highly protein bound β-lactams, profound pharmacokinetic differences were observed between comparatively morbid patients with CF and healthy volunteers. These differences could be explained by body weight and body composition for β-lactams with low protein binding. This study aimed to develop a novel population modeling approach to describe the pharmacokinetic differences between both subject groups by estimating protein binding. Eight patients with CF (lean body mass [LBM]: 39.8 ± 5.4kg) and six healthy volunteers (LBM: 53.1 ± 9.5kg) received 1027.5 mg cefotiam intravenously. Plasma concentrations and amounts in urine were simultaneously modelled. Unscaled total clearance and volume of distribution were 3\% smaller in patients with CF compared to those in healthy volunteers. After allometric scaling by LBM to account for body size and composition, the remaining pharmacokinetic differences were explained by estimating the unbound fraction of cefotiam in plasma. The latter was fixed to 50\% in male and estimated as 54.5\% in female healthy volunteers as well as 56.3\% in male and 74.4\% in female patients with CF. This novel approach holds promise for characterizing the pharmacokinetics in special patient populations with altered protein binding.}, language = {en} } @phdthesis{Schwiering2019, author = {Schwiering, Fabian}, title = {Lokalisation und Bedeutung der NO-sensitiven Guanylyl-Cyclase bei der Leberfibrose in der Maus}, doi = {10.25972/OPUS-18652}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-186520}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2019}, abstract = {Mittels der im Rahmen dieser Arbeit behandelten Untersuchungen konnten neue Erkenntnisse {\"u}ber die Rolle der NO-GC bei der Pathogenese der Lungen- und der Leberfibrose gewonnen wer- den. Infolge einer Fibrose in Lunge und Leber kommt es zu einer {\"u}berm{\"a}ßigen Akkumulation von EZM, die zum Organversagen f{\"u}hren kann. Bis jetzt existieren nur wenige Therapiem{\"o}glichkeiten, die zur Behandlung von Organfibrose dienen. Jedoch konnte bereits gezeigt werden, dass durch den Einsatz von NO-GC-Stimulatoren/Aktivatoren es zu Verbesserung/Heilung bei verschiedenen Organfibrosen kommt. Deshalb wird vermutet, dass die NO-GC eine modulatorische Rolle bei der Entwicklung einer Organfibrose einnimmt. Die Effektorzellen sind bisher unbekannt. Im ersten Teil dieser Arbeit sollten die Effektorzellen der Lunge in vitro untersucht werden. Da bekannt ist, dass in der Lunge Perizyten NO-GC exprimieren, wurde ein Protokoll etabliert, das es erm{\"o}glichte, Perizyten spezifisch aus der Lunge zu isolieren und in Kultur zu bringen. Durch den Einsatz von verschiedenen Markern wurden im Anschluss diese isolierten Perizyten weiter charakterisiert. Zum einen konnte festgestellt werden, dass die NO-GC in diesen isolierten Zellen exprimiert wird. Zum anderen stellte sich heraus, dass die Perizyten auch durch einen Marker (SM/MHC) identifiziert werden k{\"o}nnen, der eigentlich als VSMC-Marker gilt. Diese Daten waren analog zu den In-vivo-Daten von Aue et al. Zus{\"a}tzlich sollte untersucht werden, ob diese NO-GC- exprimierenden Perizyten in Kultur zu Myofibroblasten differenziert werden k{\"o}nnen. Dies gelang jedoch nicht durch Stimulation mit TGF-β1. Im zweiten Teil dieser Arbeit sollte herausgefunden werden, in welchen Zellen in der Leber die NO-GC exprimiert wird. Es konnte in vivo gezeigt werden, dass die NO-GC in der Leber in den HSC exprimiert wird. Da bekannt ist, dass die NO-GC Einfluss auf die Organfibrose nimmt, sollte die NO-GC-Expression in der Leberfibrose untersucht werden. Dabei konnte festgestellt werden, dass es zu einer gesteigerten NO-GC-Expression in der CCl4-induzierten Leberfibrose kommt. Diese war vor allem in den Myofibroblasten lokalisiert - den Zellen, die wahrscheinlich f{\"u}r den {\"u}berm{\"a}ßigen Einbau der EZM sorgen. Um den Einfluss der NO-GC auf die Leberfibrose genau- er zu untersuchen, wurde die Fibrose zwischen WT- und GCKO-Tieren verglichen. Dabei konnte beobachtet werden, dass es in den GCKO-Tieren zu einer st{\"a}rkeren Fibrose als in WT-Tieren kam, die sich durch eine vermehrte Einlagerung von Kollagen und einer erh{\"o}hten Expression von TGF-β1 auszeichnete. Damit konnte nachgewiesen werden, dass die NO-GC eine wahrschein- lich protektive Rolle in der Leberfibrose einnimmt. Im dritten Teil dieser Arbeit wurde die Rolle der HSC in der Leberfibrose genauer untersucht. Dabei konnte zum ersten mal festgestellt werden, dass sich die HSC in Subpopulation unter- teilen lassen. Durch den Einsatz von Reporterm{\"a}usen, bei denen unter dem SM/MHC- oder PDGFRβ-Promotor das Flurophor tdTomato exprimiert wurde, ließen sich die HSC in 3 Subpo- pulationen einteilen: (1) SM/MHC-Tomato- und PDGFRβ-Tomato-; (2) SM/MHC-Tomato- und PDGFRβ-Tomato+ und (3) SM/MHC-Tomato+ und PDGFRβ-Tomato-. Durch Lineage-Tracing- Versuche konnte den beschriebenen Subpopulationen Aufgaben in der Leberfibrose und in deren Aufl{\"o}sung zugeordnet werden. Die Subpopulation 1 ist in der gesunden Leber haupts{\"a}chlich in den Zonen 2 und 3 des Leberazinus lokalisiert. In der Fibrose wandern diese Zellen zu den fibrotischen Regionen und differenzieren dort zu Myofibroblasten. In der Aufl{\"o}sung der Fibrose verschwinden diese Zellen durch Apoptose aus der Leber. Die HSC-Subpopulation 2 befindet sich in der gesunden Leber in der Zone 1 des Leberazinus. Auch in und nach Aufl{\"o}sung der Leberfibrose verweilen diese Zellen dort. Zwar befindet sich die HSC-Subpopulation 3 in der ge- sunden Leber ebenfalls nur in Zone 1 des Leberazinus, jedoch wandern die Zellen in der Fibrose in die Zone 2 und 3 und ersetzen dort die HSC-Subpopulation 1, die in die fibrotische Region gewandert ist. Nach Aufl{\"o}sung der Leberfibrose hat die HSC-Subpopulation 3 die Population 1 vollst{\"a}ndig ersetzt. Nach Identifizierung der HSC-Subpopulationen stellte sich die Frage, ob ein spezifischer Aus- schnitt der NO-GC zu einer ver{\"a}nderten Leberfibrose f{\"u}hrt im Vergleich zum WT. Dazu wurde unter dem SM/MHC- und PDGFRβ-Promotor die NO-GC deletiert und die Fibrose in diesen Knockouts untersucht. W{\"a}hrend bei der Deletion der NO-GC unter dem PDGFRβ-Promotor kein Unterschied im Vergleich zum WT gesehen werden konnte, ließ sich beim SM/MHC-GCKO Unterschiede feststellen. Durch den Ausschnitt der NO-GC in den Zellen der HSC-Subpopulation 3 kam es zu einer verringerten Expression von PPARγ in der gesunden Leber. Da PPARγ als Gegenspieler von TGF-β1 fungiert, konnte eine erh{\"o}hte TGF-β1-Expression in der gesunden und fibrotischen Leber des SM/MHC-GCKO im Vergleich zum WT-Tier gesehen werden. Diese Ergebnisse sprechen daf{\"u}r, dass die NO-GC {\"u}ber die Steuerung des PPARγ ihren protektiven Effekt auf die Leberfibrose aus{\"u}bt.}, subject = {Leberfibrose}, language = {de} } @phdthesis{Wu2019, author = {Wu, Fang}, title = {Adding new functions to insulin-like growth factor-I (IGF-I) via genetic codon expansion}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-175330}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2019}, abstract = {Insulin-like growth factor-I (IGF-I) is a 70-amino acid polypeptide with a molecular weight of approximately 7.6 kDa acting as an anabolic effector. It is essential for tissue growth and remodeling. Clinically, it is used for the treatment of growth disorders and has been proposed for various other applications including musculoskeletal diseases. Unlike insulin, IGF-I is complexed to at least six high-affinity binding proteins (IGFBPs) exerting homeostatic effects by modulating IGF-I availability to its receptor (IGF-IR) on most cells in the body as well as changing the distribution of the growth factor within the organism.1-3 Short half-lived IGF-I have been the driving forces for the design of localized IGF-I depot systems or protein modification with enhanced pharmacokinetic properties. In this thesis, we endeavor to present a versatile biologic into which galenical properties were engineered through chemical synthesis, e.g., by site-specific coupling of biomaterials or complex composites to IGF-I. For that, we redesigned the therapeutic via genetic codon expansion resulting in an alkyne introduced IGF-I, thereby becoming a substrate for biorthogonal click chemistries yielding a site-specific decoration. In this approach, an orthogonal pyrrolysine tRNA synthetase (PylRS)/tRNAPyl CUA pair was employed to direct the co-translational incorporation of an unnatural amino acid—¬propargyl-L-lysine (plk)—bearing a clickable alkyne functional handle into IGF-I in response to the amber stop codon (UAG) introduced into the defined position in the gene of interest. We summarized the systematic optimization of upstream and downstream process alike with the ultimate goal to increase the yield of plk modified IGF-I therapeutic, from the construction of gene fusions resulting in (i) Trx-plk-IGF-I fusion variants, (ii) naturally occurring pro-IGF-I protein (IGF-I + Ea peptide) (plk-IGF-I Ea), over the subsequent bacterial cultivation and protein extraction to the final chromatographic purification. The opportunities and hurdles of all of the above strategies were discussed. Evidence was provided that the wild-type IGF-I yields were pure by exploiting the advantages of the pHisTrx expression vector system in concert with a thrombin enzyme with its highly specific proteolytic digestion site and multiple-chromatography steps. The alkyne functionality was successfully introduced into IGF-I by amber codon suppression. The proper folding of plk-IGF-I Ea was assessed by WST-1 proliferation assay and the detection of phosphorylated AKT in MG-63 cell lysate. The purity of plk-IGF-I Ea was monitored with RP-HPLC and SDS-PAGE analysis. This work also showed site-specific coupling an alkyne in plk-IGF-I Ea by copper (I)-catalyzed azide-alkyne cycloaddition (CuAAC) with potent activities in vitro. The site-specific immobilization of plk-IGF-I Ea to the model carrier (i.e., agarose beads) resulted in enhanced cell proliferation and adhesion surrounding the IGF-I-presenting particles. Cell proliferation and differentiation were enhanced in the accessibility of IGF-I decorated beads, reflecting the multivalence on cellular performance. Next, we aimed at effectively showing the disease environment by co-delivery of fibroblast growth factor 2 (FGF2) and IGF-I, deploying localized matrix metalloproteinases (MMPs) upregulation as a surrogate marker driving the response of the drug delivery system. For this purpose, we genetically engineered FGF2 variant containing an (S)-2-amino-6-(((2-azidoethoxy)carbonyl)amino)hexanoic acid incorporated at its N-terminus, followed by an MMPs-cleavable linker (PCL) and FGF2 sequence, thereby allowing site-directed, specific decoration of the resultant azide-PCL-FGF2 with the previously mentioned plk-IGF-I Ea to generate defined protein-protein conjugates with a PCL in between. The click reaction between plk-IGF-I Ea and azide-PCL-FGF2 was systematically optimized to increase the yield of IGF-FGF conjugates, including reaction temperature, incubation duration, the addition of anionic detergent, and different ratios of the participating biopharmaceutics. The challenge here was that CuAAC reaction components or conditions might oxidize free cysteines of azide-PCL-FGF2 and future work needs to present the extent of activity retention after conjugation. Furthermore, our study provides potential options for dual-labeling of IGF-I either by the introduction of unnatural amino acids within two distinct positions of the protein of interest for parallel "double-click" labeling of the resultant plk-IGF-I Ea-plk or by using a combination of enzymatic-catalyzed and CuAAC bioorthogonal coupling strategies for sequentially dual-labeling of plk-IGF-I Ea. In conclusion, genetic code expansion in combination with click-chemistry provides the fundament for novel IGF-I analogs allowing unprecedented site specificity for decoration. Considerable progress towards IGF-I based therapies with enhanced pharmacological properties was made by demonstrating the feasibility of the expression of plk incorporated IGF-I using E. coli and retained activity of unconjugated and conjugated IGF-I variant. Dual-labeling of IGF-I provides further insights into the functional requirements of IGF-I. Still, further investigation warrants to develop precise IGF-I therapy through unmatched temporal and spatial regulation of the pleiotropic IGF-I.}, subject = {Insulin-like Growth Factor I}, language = {en} } @phdthesis{Riad2019, author = {Riad, Noura}, title = {The Development of Dualsteric Ligands for the Elucidation of Mode of Activation of Muscarinic Receptors and their Selective Signaling}, doi = {10.25972/OPUS-17928}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-179282}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2019}, abstract = {GPCRs, particularly muscarinic receptors (mAChRs), are significant therapeutic targets in many physiological conditions. The significance of dualsteric hybrids selectively targeting mAChR subtypes is their great advantage in avoiding undesired side effects. This is attained by exploitation of the high affinity of ligand-binding to the orthosteric site and the structural diversity of the allosteric site to target an individual mAChR subtype, as well as offering signal bias to avoiding undesired transduction pathways. Furthermore, dualsteric targeting of mAChR subtypes helps in the elucidation of the physiological role of each individual mAChR subtype. The first project was the attempt of synthesis of the M2-preferring ligand AFDX-384. AFDX-384 is known to preferentially bind to the M2 receptor subtype as an orthosteric antagonist, with partial interaction with residues in the allosteric site. This project aimed to re-trace the synthesis route of AFDX-384, to open the door to its upscaling and the future synthesis of AFDX-type dualsteric ligands. The multi-step synthesis of AFDX-384 is achieved through the synthesis of its 2 precursors, the chloro acyl derivative VIII and the piperidinyl derivative IV. Upscaled synthesis of the piperidinyl derivative IV was attained. Synthesis of the chloro acyl compound VIII was attempted. Several trials to synthesize the benzopyridodiazepine nucleus as well as its chloro-acylation resulted in the production of the novel crystal structures V and VI. X-ray crystallography was also done for crystallized molecules of the closed-ring benzopyridodiazepine VII that was previously synthesized. Chloro-acylation reactions of compound VII using phosgene seem to be attainable when done using reflux overnight. However, the use of methanol to aid in elution during silica gel column chromatography converted the expected product to the carbamate analogue IX. Hence, further attempts in purification should refrain from the use of methanol. The use of triphosgene instead of phosgene demonstrates a cleaner route for further upscaled synthesis. The second project was the synthesis of dualsteric ligands involving variable orthosteric and allosteric moieties. Four different types of hybrids have been created over multiple steps. Dualsteric ligands have been synthesized using either a phthalimido- or 1,8-naphthalimidopropylamino moiety as the allosteric-binding group, coupled to either N-desmethyl pirenzepine or N-desmethyl clozapine using variable chain lengths. Furthermore, the synthesis of the dualsteric ligands involving N-desmethyl clozapine linked to either the super-agonist iperoxo or acetylcholine, and being connected using variable alkane chain lengths. Several reaction conditions have been investigated throughout the analysis of the optimal condition to conduct the critical final step of synthesis of these dualsteric hybrids, which involves the linking of the two segments of the hybrid together. The optimal method, which produced the least side products and highest yield, was to connect the two intermediates of the compound in absence of base, catalyst or microwaves while stirring at 35 °C for several days using acetonitrile as solvent (silica gel TLC monitoring, 0.2 M aqueous KNO3/MeOH 2:3). The ideal purification methods for the final compounds were found to be either crystallization from the reaction medium or using C18 reverse phase silica gel flash chromatography (using H2O/MeOH solvent system). All the hybrids will be subjected to pharmacological testing using the appropriate FRET assays.}, subject = {Muscarinrezeptor}, language = {en} } @phdthesis{Kuhn2019, author = {Kuhn, Maximilian}, title = {Strukturbasiertes Design von MIP-Inhibitoren und computergest{\"u}tzte Selektivit{\"a}tsuntersuchung gegen{\"u}ber MIP- und humanen FKB-Proteinen}, doi = {10.25972/OPUS-16575}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-165757}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2019}, abstract = {Bakterielle und parasit{\"a}re MIP-Proteine stellen wichtige Virulenzfaktoren dar, deren Inhibition das {\"U}berleben der Erreger sowie deren Penetration in menschliche Zellen stark einschr{\"a}nken kann. In dieser Arbeit standen die MIP-Proteine von Burkholderia pseudomallei (Ausl{\"o}ser der Melioidose) und Legionella pneumophila (Legion{\"a}rskrankheit) im Fokus. Außerdem wurde das MIP-Protein von Trypanosoma cruzi (Chagas-Krankheit) untersucht. Die strukturverwandten humanen FKB-Proteine FKBP12 und FKBP52 sind relevante „off-targets", wie Experimente mit Knockout-M{\"a}usen gezeigt haben. Ziel dieser Arbeit war die Verbesserung von bekannten MIP-Inhibitoren im Hinblick auf ihre Affinit{\"a}t und Selektivit{\"a}t f{\"u}r MIP-Proteine gegen{\"u}ber den beiden genannten FKB-Proteinen bei gleichzeitig verbesserter L{\"o}slichkeit, mit Hilfe von in silico Methoden. Ausgangspunkt waren hierbei zwei von Dr. Christina Juli und Dr. Florian Seufert entwickelte Leitstrukturen, welche ein Pipecolins{\"a}uregrundger{\"u}st aufweisen. Diese Referenzliganden beinhalten einen 3,4,5-Trimethoxyphenylring (TMPR, vgl. Ref_t) bzw. einen Pyridinylring (Ref_p). Beim Vergleich von insgesamt 32 MIP- und FKB-Proteinen konnten in zwei Loop-Bereichen, welche 50er bzw. 80er Loop genannt werden, relevante Unterschiede in der Aminos{\"a}uresequenz identifiziert werden. Die Nummerierung bezieht sich stets auf FKBP12. Diese Unterschiede ließen sich zum Design von vergleichsweise selektiv an MIP-Proteine bindenden Molek{\"u}len nutzen. Der 50er Loop ist in nahezu allen MIP-Proteinen (jedoch nicht in BpsMIP) im Vergleich zu den FKB-Proteinen um zwei Aminos{\"a}uren verk{\"u}rzt. Dadurch befindet sich das Proteinr{\"u}ckgrat von LpnMIP (Gln49) und TcrMIP (Arg49) n{\"a}her am Zentrum der Bindetasche (definiert als Ile56, welches durch die Pipecolins{\"a}ureesterfunktion der Liganden adressiert wird). MD-Simulationen der beiden Apoproteine belegten, dass die geringere Distanz nicht durch Artefakte beim Modellieren der Strukturen bedingt ist. Aufbauend auf dieser Erkenntnis wurde gezeigt, dass der Pyridinylring von Ref_p eine Wasserstoffbr{\"u}cke zu Gln49 ausbildet. Experimentell wurde dieser Befund durch eine entsprechende chemische Verschiebung der Aminos{\"a}ure im NMR-Experiment von Dr. Kristian Schweimer best{\"a}tigt. Durch {\"U}berbr{\"u}ckung des Pipecolins{\"a}urerings (Ligand 6bp) konnte die Wasserstoffbr{\"u}cke in MD-Simulationen weiter stabilisiert werden. Durch Rechnungen zur Absch{\"a}tzung der freien Bindungsenthalpien (mittels LIE und MM/GBSA) wurde eine erh{\"o}hte Affinit{\"a}t von 6bp im Vergleich zu Ref_p in LpnMIP ermittelt. Im Laufe der Arbeit wurde anhand von pIC50-Werten, welche von Dr. Mathias Weiwad bestimmt wurden, erkannt, dass Liganden mit Pyridinylring oftmals eine bessere Affinit{\"a}t in LpnMIP aufweisen als die entsprechenden Liganden mit TMPR. Durch MD Simulationen wurde nachgewiesen, dass der TMPR in LpnMIP nur schwer an der in den anderen Proteinen bevorzugten Position binden kann. Grund hierf{\"u}r ist die Mutation einer Aminos{\"a}ure (zu Pro57) in diesem Bereich von LpnMIP: Diese verf{\"u}gt {\"u}ber eine wenig flexible Seiten-kette, an welche sich der TMPR auf Grund seiner Rigidit{\"a}t nicht anpassen kann, was die Interaktion zwischen Protein und Ligand st{\"o}rt. Der Pyridinylring von Ref_p ist hiervon nicht betroffen, da er bevorzugt an einer anderen Stelle (Gln49, s. o.) bindet. Der 80er Loop weist in vielen MIP-Proteinen deutlich hydrophobere Aminos{\"a}uren auf als in FKB-Proteinen. Von besonderem Interesse ist die Position 90, da hier in BpsMIP und LpnMIP sterisch weniger anspruchsvolle Aminos{\"a}uren (Val, Pro) vorliegen als in den bei-den FKB-Proteinen (Ile, Lys). Dieser Unterschied wurde mit kleinen hydrophoben Substituenten am Phenylring der Liganden adressiert. Bereits im Docking zeigten sich die positiven Effekte der para-Substitution durch Halogenatome oder eine Methylgruppe. Die von Dr. Mathias Weiwad und Dr. Mirella Vivoli ermittelten pIC50- bzw. pKi-Werte best{\"a}tigten diesen Trend. Zugleich nahm die Affinit{\"a}t zu FKBP12 deutlich ab. Bei der Untersuchung der Referenzliganden sowie deren Chlor- und Bromderivate in MD-Simulationen zeigte sich, dass der Phenylring der Liganden in den MIP-Proteinen bevorzugt in Richtung des 80er Loops orientiert ist; in den FKB-Proteinen liegt er hingegen um etwa 110° gedreht vor und kann somit schlechter mit der Bindetasche interagieren. Besonders ausgepr{\"a}gt ist dieser Effekt in FKBP12. Basierend auf diesen Ergebnissen wurde der Phenylring durch einen 4-Bromo-1H-imidazol-2-ylsubstituenten ersetzt (Ligand 8ap). Dieser ist in der Lage, in der erwarteten Orientierung im Bereich des 80er Loops von BpsMIP zu binden und gleichzeitig eine stabile Wasserstoffbr{\"u}cke zu Asp37 auszubilden. Hieraus resultiert f{\"u}r den Liganden eine deutlich h{\"o}here Affinit{\"a}t in LIE- und MM/GBSA-Rechnungen; in FKBP12 blieb sie auf Grund der dort instabilen Interaktion unver{\"a}ndert. Die berechneten Energien k{\"o}nnen unmittelbar f{\"u}r einen relativen Vergleich verschiedener Liganden in einer Bindetasche verwendet werden. F{\"u}r die Vorhersage von pKi- bzw. pIC50-Werten in den verschiedenen Proteinen ist eine Kalibrierung gegen die gemessenen Affinit{\"a}ten erforderlich. Dies wurde f{\"u}r BpsMIP durchgef{\"u}hrt, indem eine lineare Korrelation zwischen den pKi- bzw. pIC50-Werten und den mit MM/GBSA ermittelten Energien aufgestellt wurde. F{\"u}r LIE wurde auf publizierte Werte von Lamb et al. zur{\"u}ckgegriffen. Die berechneten Affinit{\"a}ten stimmen f{\"u}r die bereits getesteten Inhibitoren gut mit den experimentellen pKi- und pIC50-Werten {\"u}berein. Anhand der Modelle werden f{\"u}r 8ap Werte vorhergesagt, die besser als die experimentellen Affinit{\"a}ten bekannter Liganden sind. Idealerweise k{\"o}nnen auch aus den Scores, die durch Docking erhalten werden, bereits R{\"u}ckschl{\"u}sse auf die Affinit{\"a}ten der Liganden gezogen werden. F{\"u}r die untersuchten Proteine war dies, auf Grund des engen Bereichs der experimentell ermittelten pKi- und pIC50-Werte, nicht mit hinreichender Richtigkeit m{\"o}glich. Um die Scores dennoch f{\"u}r die Beurteilung neuer Liganden verwenden zu k{\"o}nnen, wurden logistische Regressionsmodelle erstellt. Anhand dieser kann abgesch{\"a}tzt werden, ob ein Molek{\"u}l in BpsMIP submikromolare Affinit{\"a}t aufweist. Die Richtigkeit dieser Vorhersagemodelle konnte durch die Ber{\"u}cksichtigung dreier weiterer Deskriptoren (Konfiguration am Stereozentrum der Pipecolins{\"a}ure, Molekulargewicht und logD-Wert) deutlich verbessert werden, wobei die AUC der entsprechenden ROC-Kurven Werte bis zu 0.9 erreichte. Diese Modelle k{\"o}nnen f{\"u}r die Postprozessierung eines Dockings angewendet werden, um die vielversprechendsten Kandidaten zu identifizieren und anschließend in rechnerisch anspruchsvolleren MD-Simulationen genauer zu untersuchen. Mit dieser Arbeit wurde zur Weiterentwicklung der Leitstrukturen Ref_t und Ref_p beigetragen. Viele der getesteten Derivate wiesen deutlich verbesserte L{\"o}slichkeit bei gleichbleibender Affinit{\"a}t auf. Ferner wurden erstmalig detailliert die Unterschiede in den Bindetaschen zwischen 32 MIP- und FKB-Proteinen evaluiert. Hiervon wurden f{\"u}nf in MD-Simulationen als Apoprotein und im Komplex mit verschiedenen Inhibitoren verglichen. Anhand dieser Simulationen wurde nachgewiesen, dass jeweils eine Aminos{\"a}ure in BpsMIP und LpnMIP im Vergleich zum wichtigsten „off-target" FKBP12 selektiv durch eine Wasserstoffbr{\"u}cke adressiert werden kann. Durch LIE- und MM/GBSA-Rechnungen konnte gezeigt werden, dass in diesen hochkonservierten Bindetaschen eine bedeutende Modulation der Affinit{\"a}t zugunsten von BpsMIP m{\"o}glich ist.}, subject = {Computational chemistry}, language = {de} } @article{DirimanovHoegger2019, author = {Dirimanov, Stoyan and H{\"o}gger, Petra}, title = {Screening of inhibitory effects of polyphenols on Akt-phosphorylation in endothelial cells and determination of structure-activity features}, series = {Biomolecules}, volume = {9}, journal = {Biomolecules}, number = {6}, issn = {2218-273X}, doi = {10.3390/biom9060219}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-197333}, pages = {219}, year = {2019}, abstract = {Polyphenols exert beneficial effects in type 2 diabetes mellitus (T2DM). However, their mechanism of action remains largely unknown. Endothelial Akt-kinase plays a key role in the pathogenesis of cardiovascular complications in T2DM and therefore the modulation of its activity is of interest. This work aimed to characterize effects of structurally different polyphenols on Akt-phosphorylation (pAkt) in endothelial cells (Ea.hy926) and to describe structure-activity features. A comprehensive screening via ELISA quantified the effects of 44 polyphenols (10 µM) on pAkt Ser473. The most pronounced inhibitors were luteolin (44 ± 18\%), quercetin (36 ± 8\%), urolithin A (35 ± 12\%), apigenin, fisetin, and resveratrol; (p < 0.01). The results were confirmed by Western blotting and complemented with corresponding experiments in HUVEC cells. A strong positive and statistically significant correlation between the mean inhibitory effects of the tested polyphenols on both Akt-residues Ser473 and Thr308 (r = 0.9478, p = 0.0003) was determined by immunoblotting. Interestingly, the structural characteristics favoring pAkt inhibition partially differed from structural features enhancing the compounds' antioxidant activity. The present study is the first to quantitatively compare the influence of polyphenols from nine different structural subclasses on pAkt in endothelial cells. These effects might be advantageous in certain T2DM-complications involving over-activation of the Akt-pathway. The suggested molecular mode of action of polyphenols involving Akt-inhibition contributes to understanding their effects on the cellular level.}, language = {en} } @article{PenagosCalveteDuqueMarimonetal.2019, author = {Penagos-Calvete, Diana and Duque, Valeria and Marimon, Claudia and Parra, Diana M. and Restrepo-Arango, Sandra K. and Scherf-Clavel, Oliver and Holzgrabe, Ulrike and Montoya, Guillermo and Salamanca, Constain H.}, title = {Glycerolipid composition and advanced physicochemical considerations of sacha inchi oil toward cosmetic products formulation}, series = {Cosmetics}, volume = {6}, journal = {Cosmetics}, number = {4}, issn = {2079-9284}, doi = {10.3390/cosmetics6040070}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-193857}, year = {2019}, abstract = {Sacha inchi oil is a premier raw material with highly nutritional and functional features for the foodstuff, pharmaceutical, beauty, and personal care industries. One of the most important facts about this oil is the huge chemical content of unsaturated and polyunsaturated fatty acids. However, the current available information on the characterization of the triglyceride composition and the advance physicochemical parameters relevant to emulsion development is limited. Therefore, this research focused on providing a detailed description of the lipid composition using high-resolution tandem mass spectrometry and thorough physicochemical characterization to find the value of the required hydrophilic-lipophilic balance (HLB). For this, a study in the interfacial tension was evaluated, followed by the assessment of different parameters such as creaming index, droplet size, viscosity, zeta potential, pH, and electrical conductivity for a series emulsified at thermal stress condition. The results show that fatty acids are arranged into glycerolipids and the required HLB to achieve the maximum physical stability is around 8.}, language = {en} } @article{PoepplerLuebtowSchlauersbachetal.2019, author = {P{\"o}ppler, Ann-Christin and L{\"u}btow, Michael M. and Schlauersbach, Jonas and Wiest, Johannes and Meinel, Lorenz and Luxenhofer, Robert}, title = {Strukturmodell von Polymermizellen in Abh{\"a}ngigkeit von der Curcumin-Beladung mithilfe von Festk{\"o}rper-NMR-Spektroskopie}, series = {Angewandte Chemie}, volume = {131}, journal = {Angewandte Chemie}, number = {51}, doi = {10.1002/ange.201908914}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-212513}, pages = {18712-18718}, year = {2019}, abstract = {Detaillierte Einblicke in die Struktur von mit Wirkstoffen beladenen Polymermizellen sind rar, aber wichtig um gezielt optimierte Transportsysteme entwickeln zu k{\"o}nnen. Wir konnten beobachten, dass eine Erh{\"o}hung der Curcumin-Beladung von Triblockcopolymeren auf Basis von Poly(2-oxazolinen) und Poly(2-oxazinen) schlechtere Aufl{\"o}sungseigenschaften nach sich zieht. Mitthilfe von Festk{\"o}rper-NMR-Spektroskopie und komplement{\"a}ren Techniken ist es m{\"o}glich, ein ladungsabh{\"a}ngiges Strukturmodell auf molekularer Ebene zu erstellen, das eine Erkl{\"a}rung f{\"u}r die beobachteten Unterschiede liefert. Dabei belegen die {\"A}nderungen der chemischen Verschiebungen und Kreuzsignale in 2D-NMR-Experimenten die Beteiligung des hydrophoben Polymerblocks an der Koordination der Curcumin-Molek{\"u}le, w{\"a}hrend bei h{\"o}herer Beladung auch eine zunehmende Wechselwirkung mit dem hydrophilen Polymerblock beobachtet wird. Letztere k{\"o}nnte elementar f{\"u}r die Stabilisierung von ultrahochbeladenen Polymermizellen sowie das Design von verbesserten Wirkstofftransportsystemen sein.}, language = {de} } @article{MansourSteigerNageletal.2019, author = {Mansour, Ahmed M. and Steiger, Christoph and Nagel, Christoph and Schatzschneider, Ulrich}, title = {Wavelength-dependent control of the CO release kinetics of manganese(I) tricarbonyl PhotoCORMs with benzimidazole coligands}, series = {European Journal of Inorganic Chemistry}, volume = {2019}, journal = {European Journal of Inorganic Chemistry}, number = {42}, doi = {10.1002/ejic.201900894}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-218362}, pages = {4572-4581}, year = {2019}, abstract = {A series of photoactivatable CO-releasing molecules (PhotoCORMs) was prepared from manganese pentacarbonyl bromide and 1H-benzimidazol-2-ylmethyl-(N-phenyl)amine ligands (L) bearing different electron-donating and electron-withdrawing groups R = H, 4-CH\(_3\), 4-OCH\(_3\), 4-Cl, 4-NO\(_2\), 2-, 3-, and 4-COOCH\(_3\) on the phenyl substituent to give octahedral manganese(I) complexes of the general formula [MnBr(CO)\(_3\)(L)]. Aerated DMSO solutions of the compounds are stable in the dark for 16 h with no CO release. However, the compounds rapidly release CO upon illumination at 412-525 nm, depending on the substitution pattern. Its influence on the photophysical and photochemical properties was systematically explored using UV/Vis spectroscopy and CO release measurements with a commercial gas sensor system. In the nitro-substituted compound, the electronically excited state switched from benzimidazole- to phenyl-centered, leading to a markedly different photochemical behavior of this visible-light activated PhotoCORM.}, language = {en} } @article{PoepplerLuebtowSchlauersbachetal.2019, author = {P{\"o}ppler, Ann-Christin and L{\"u}btow, Michael M. and Schlauersbach, Jonas and Wiest, Johannes and Meinel, Lorenz and Luxenhofer, Robert}, title = {Loading dependent Structural Model of Polymeric Micelles Encapsulating Curcumin by Solid-State NMR Spectroscopy}, series = {Angewandte Chemie International Edition}, volume = {58}, journal = {Angewandte Chemie International Edition}, number = {51}, doi = {10.1002/anie.201908914}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-206705}, pages = {18540-18546}, year = {2019}, abstract = {Detailed insight into the internal structure of drug-loaded polymeric micelles is scarce, but important for developing optimized delivery systems. We observed that an increase in the curcumin loading of triblock copolymers based on poly(2-oxazolines) and poly(2-oxazines) results in poorer dissolution properties. Using solid-state NMR spectroscopy and complementary tools we propose a loading-dependent structural model on the molecular level that provides an explanation for these pronounced differences. Changes in the chemical shifts and cross-peaks in 2D NMR experiments give evidence for the involvement of the hydrophobic polymer block in the curcumin coordination at low loadings, while at higher loadings an increase in the interaction with the hydrophilic polymer blocks is observed. The involvement of the hydrophilic compartment may be critical for ultrahigh-loaded polymer micelles and can help to rationalize specific polymer modifications to improve the performance of similar drug delivery systems.}, language = {en} } @article{BulittaJiaoLandersdorferetal.2019, author = {Bulitta, J{\"u}rgen B. and Jiao, Yuanyuan and Landersdorfer, Cornelia B. and Sutaria, Dhruvitkumar S. and Tao, Xun and Shin, Eunjeong and H{\"o}hl, Rainer and Holzgrabe, Ulrike and Stephan, Ulrich and S{\"o}rgel, Fritz}, title = {Comparable Bioavailability and Disposition of Pefloxacin in Patients with Cystic Fibrosis and Healthy Volunteers Assessed via Population Pharmacokinetics}, series = {Pharmaceutics}, volume = {11}, journal = {Pharmaceutics}, number = {7}, issn = {1999-4923}, doi = {10.3390/pharmaceutics11070323}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-197221}, pages = {323}, year = {2019}, abstract = {Quinolone antibiotics present an attractive oral treatment option in patients with cystic fibrosis (CF). Prior studies have reported comparable clearances and volumes of distribution in patients with CF and healthy volunteers for primarily renally cleared quinolones. We aimed to provide the first pharmacokinetic comparison for pefloxacin as a predominantly nonrenally cleared quinolone and its two metabolites between both subject groups. Eight patients with CF (fat-free mass [FFM]: 36.3 ± 6.9 kg, average ± SD) and ten healthy volunteers (FFM: 51.7 ± 9.9 kg) received 400 mg pefloxacin as a 30 min intravenous infusion and orally in a randomized, two-way crossover study. All plasma and urine data were simultaneously modelled. Bioavailability was complete in both subject groups. Pefloxacin excretion into urine was approximately 74\% higher in patients with CF compared to that in healthy volunteers, whereas the urinary excretion of metabolites was only slightly higher in patients with CF. After accounting for body size and composition via allometric scaling by FFM, pharmacokinetic parameter estimates in patients with CF divided by those in healthy volunteers were 0.912 for total clearance, 0.861 for nonrenal clearance, 1.53 for renal clearance, and 0.916 for volume of distribution. Nonrenal clearance accounted for approximately 90\% of total pefloxacin clearance. Overall, bioavailability and disposition were comparable between both subject groups.}, language = {en} }